Edinburgh firm Angel Biotechnology wins US contract

Glass pipette dispenses fluid into test tubes Angel's products are mainly used in pre-clinical studies and clinical trials

A Scottish biopharmaceutical company has won a contract worth more than £800,000 to develop an interferon product for a US firm.

Edinburgh-based Angel Biotechnology will carry out the work for Louisiana firm TransGenRx at its facility at Cramlington, near Newcastle-upon-Tyne.

Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as stem cells.

Its products are mainly used in pre-clinical studies and clinical trials.

The contract manufacturer has two facilities - one at Pentlands Science Park near Edinburgh, where it employs 38 people, and the site in Cramlington, which is expected to employ up to 10 people by the end of 2012.

Angel acting chief executive Stewart White: "This contract demonstrates the confidence which TransGenRx has in the ability of Angel to develop and manufacture complex proteins and reinforces the board's decision to invest in this additional capacity."

More on This Story

The BBC is not responsible for the content of external Internet sites

More Scotland business stories

RSS

Features

Copyright © 2015 BBC. The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.